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A Two - institution study of risk factors for pancreatitis after endoscopic 
retrograde cholangiopancreatography for transpapillar y biliar y stent 
placement in patients with malignant biliary obstruction
Ryuichi Yamamoto1)＊, Ko Nishikawa2), Shuko Ishida1), 
Masatomo Takahashi1), Maiko Harada1), Yasuyo Osafune1), 
Shingo Kato1), Sumiko Nagoshi1), Koji Yakabi1)
1) Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, 
Saitama, Japan
2) Department of the Gastroenterology, Ageo Central General Hospital, Ageo, Saitama Prefecture, Japan
【Objective】To evaluate the risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography 
(ERCP) for biliary stent placement in patients with malignant biliary obstruction (MBO).
【Methods】This retrospective study included consecutive MBO patients who under went ERCP-guided 
transpapillary biliary stent placement over a period of 5.5 years at two tertiary referral academic medical centers. 
Of 100 eligible patients identified, 67 received a WallflexTM self-expandable metallic stent (Boston Scientific 
Cooperation, Japan; SEMS group) and 33 received a FleximaTM plastic stent (Boston Scientific; PS group). The 
etiology of MBO was similar between the two groups, with pancreatic cancer accounting for 53% cases. The main 
outcome measurements were identifiable risk factors for post-ERCP pancreatitis (PEP).
【Results】The overall PEP rate was 3.0%, with no significant difference between the SEMS and PS groups. Totally, 
7.1% and 2.3% patients who did and did not undergo endoscopic sphincterotomy (EST) before biliary stenting, 
respectively, developed PEP. The median duration of stent patency in the 8-mm SEMS, 10-mm SEMS, and PS 
groups was 136, 140, and 79 days, respectively, for patients with pancreatic cancer and in the 8-mm SEMS, 10-mm 
SEMS, and PS groups was 126, 166, and 137 days, respectively, for patients without pancreatic cancer. Multivariate 
analysis identified 6 factors that were not associated with PEP. PEP rates according to the presence or absence of 
EST before stent placement, stent type, stent size, and indications were not significantly different. 
【Conclusion】The characteristics of the biliary stent and the performance of EST before stent placement are not 
significant risk factors for PEP in patients with MBO who underwent transpapillary biliary stent placement.
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IIntroduction
Malignant biliary obstruction (MBO) is frequently 
encountered in the practice of gastroenterology 1 -3).
Endoscopic retrograde cholangiopancreatography 
(ERCP) is the preferred method of providing biliary 
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drainage because of its cost-ef fectiveness, and it is 
also the first-line therapy for the treatment of MBO4, 5).  
Biliary stent placement using ERCP resolves jaundice 
and pain and improves the quality of life in patients 
with MBO6). Post-ERCP pancreatitis (PEP) is the most 
common complication of ERCP-guided biliary stent 
placement for MBO. Although it is generally mild, 
severe complications and death have been reported 
to occur in patients with PEP1 -3). This study aimed to 
evaluate the risk factors for PEP in patients with MBO 
who underwent ERCP-guided biliary stent placement.
Methods 
The medical records of 100 patients with MBO who 
underwent ERCP-guided transpapillary biliary stent 
placement from April 2005 to August 2011 at the 
Saitama Medical Center of Saitama Medical University 
and Ageo Central General Hospital were retrospectively 
reviewed. This study was approved by the Saitama 
Medica l  Center,  Sa i tama Medica l  Univers i ty 
Institutional Review Board (No. 785). Of the 100, 67 
patients received a Self-Expandable Metallic Stent 
(SEMS group; 39 covered stents and 28 uncovered 
stents) and 33 received a Plastic Stent (7Fr-10Fr) (PS 
group). The clinical characteristics of the patients 
included in the study are summarized in Table 1. The 
Single-step group included 33 men (49.3%) and 34 
women (50.7%) with a mean age of 74.6 years, whereas 
the PS group included 18 men (54.5%) and 15 women 
(45.5%) with a mean age of 66.9 years. Pancreatic 
cancer was the cause of MBO in 36 patients (53.7%) 
in the SEMS group and 16 patients (48.5%) in the PS 
group, whereas cholangiocarcinoma and gallbladder 
cancer were the cause in 31 patients (46.3%) in the 
SEMS group and 17 patients (51.5%) in the PS group. 
Patient demographics and data regarding stricture 
location and stent sizes are shown in Fig. 1. PEP was 
defined using standard criteria: new or worsening acute 
postprocedural abdominal pain in conjunction with 
an elevation in serum amylase or lipase levels greater 
than 3 times the upper limit of normal, with or without 
radiographic evidence of acute pancreatitis6).
Statistical analysis
We reviewed the medical records and radiological 
images of each patient undergoing the stent placement 
procedure. The following variables were assessed 
by multivariate analysis (Chi-square test or Fisher’s 
exact test) to identify the potential risk factors for 
PEP: gender, age, etiology of MBO (pancreatic cancer 
vs. non-pancreatic cancer), MPD tumor involvement, 
procedure for the ampulla, and type of SEMS used 
(covered or uncovered). Odds ratios (ORs) with 95% 
confidence inter vals (CIs) were computed for all 
variables. Statistical tests were two-sided, and a P value 
of <0.05 was considered statistically significant. 
Results
The rates of PEP in the two groups in this study are 
summarized in Tables 2 and 3. The overall rate of PEP 
Table 1.
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was 3.0%. We classified all cases of PEP as mild using 
consensus criteria. Hospitalization was required for 
all patients, with a mean post-ERCP length of stay of 
11 days. No significant dif ference in PEP rate was 
obser ved between the PS group and SEMS group 
(3.0% vs. 2.99%, P = 0.54). The performance of EST 
prior to stenting was not associated with a lower rate 
of PEP; 7.1% (1/14) patients who under went EST 
developed PEP while 2.3% (2/86) patients who did not 
undergo the procedure developed PEP (P = 0.89). The 
duration of stent patency in patients with and without 
pancreatic cancer are shown in Fig. 2 and 3. The 
median duration of stent patency in the 8-mm SEMS 
group, the 10-mm SEMS group, and the PS group was 
136, 140, and 79 days, respectively for the patients with 
pancreatic cancer (P = 0.88) and 126, 166, and 137 days, 
respectively, in the PS group (P = 0.82). A multivariate 
analysis of risk factors for PEP are shown in Table 4. 
PEP rates according to the presence or absence of 
EST before stent placement, stent type, stent size, and 
indications were not significantly different.
Fig. 1. Patient demographics and data regarding stricture location and stent sizes are shown.
Table 2.
Table 3.
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Discussion
The performance of EST before biliary stenting is 
an established technique used in selected patients 
to facilitate biliar y stone extraction, enhance the 
placement of large-diameter (10 - 11.5 Fr) plastic stents, 
and treat bile leakage, among other indications 7 -9). 
There is currently no standardization of the indications 
for EST before transpapillary SEMS placement. This is 
an important clinical question that should be addressed 
for several reasons.
   First, the repor ted incidence of pancreatitis in 
patients with tumors of the main pancreatic duct 
(MPD) is low 10, 11). In addition, because of their 
greater diameter compared with that of PSs, SEMSs 
have superior patency and are increasingly preferred 
for the treatment of unresectable MBO in patients 
whose life expectancy is at least 6 months 12 - 13). 
Nevertheless, among patients with unresectable MBO 
and a reasonable life expectancy, SEMS remains the 
preferred device because of its superior patency rate.
   The overall rate of PEP was 3.0% in the total 
Fig. 3. Duration of stent patency in patients without pancreatic cancer are shown. No significant difference was observed 
among the 8 mm SEMS, 10 mm SEMS and PS groups.
Fig. 2. Duration of stent patency in patients with pancreatic cancer are shown. No significant difference was observed among 
the 8 mm SEMS, 10 mm SEMS and PS groups.
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population of patients who underwent transpapillary 
biliar y stenting for MBO between April 2005 and 
August 2011 in this study.
No significant difference in PEP rate was observed 
between the SEMS group and the PS group (3.0% vs. 
2.99%, P = 0.54). In addition, the performance of EST 
prior to biliary stenting was not associated with a lower 
rate of PEP (with EST, 7.1% (1/14 patients); without 
EST, 2.3% (2/86 patients; P = 0.89). 
The results of multivariate analysis of risk factors for 
PEP are shown in Table 4. There was no significant 
dif ference in PEP rates calculated according to the 
presence or absence of EST prior to stent placement, 
stent type, stent size, and indications. Although SEMSs 
have superior patency compared with PSs, the risk 
factors for PEP following transpapillary stent placement 
should be taken into consideration. Prior studies have 
reported that self-expanding metal stent placement 
without biliary sphincterotomy was not associated with 
pancreatitis14 - 16). The physician must use sound clinical 
judgement while making the decision to perform EST 
prior to transpapillary SEMS placement.
SEMS have superior patency to plastic stents due to 
their grater diameter, which may increase the incidence 
of pancreatitis. However, in the present study, we did 
not identify a relationship between stent size and the 
incidence of pancreatitis. Covered SEMS are associated 
with a higher risk of pancreatitis because of obstruction 
of the pancreatic duct orifice by the cover. However, 
our study showed that none of the SEMS- specific risk 
factors, including the use of covered SEMS, contributed 
to pancreatitis. 
Our study has some limitations. First, the study 
population was too small for meaningful analysis 
of the risk factors for PEP. Second, this was not a 
prospective study; therefore, selection biases were 
present with regard to the type of SEMS used and the 
procedure employed for cannulation of the ampulla. 
The type of procedure was selected at the discretion 
of the endoscopists, so its impact on the incidence of 
pancreatitis could not be clearly established.
Conclusions
The characteristics of the biliar y stent and the 
performance of EST before stent placement are not 
significant risk factors for PEP in patients with MBO 
who undergo transpapillary biliary stent placement.
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悪性胆道狭窄に対する内視鏡的胆管ステント留置におけるERCP後膵炎危険因子の検討− 施設共同研究−
山本　龍一 )，西川　稿 )，石田　周幸 )，高橋　正朋 )，長船　靖代 )，加藤　真吾 )，名越　澄子 )，
屋嘉比　康治 )
【目的】悪性胆道狭窄に対する内視鏡的胆管ステント留置におけるERCP後膵炎の危険因子を明らかにする．
【対象と方法】対象は2005年4月から2011年8月の間に埼玉医科大学総合医療センター及び上尾中央総合病院にて
悪性胆道狭窄に対しERCP下に内視鏡的胆管ステント留置した100例．Self expandable metallic stent（SEMS）を
留置した67例をSEMS groupとしPlastic stent（PS）を留置した33例をPS groupとした．ERCP後膵炎に寄与する
危険因子を検討した．
【結果】全症例のERCP後膵炎の発症率は3.0％でありSEMS groupは7.1％，PS groupは2.3％であり両群に差を
認めなかった．膵癌患者のステントの開存期間中央値はSEMS group（8 mm）は136日，SEMS group（10 mm）は
140日，PS groupは79日であった．膵癌以外の患者のステントの開存期間中央値はSEMS group（8 mm）は126日，
SEMS group（10 mm）は166日，PS groupは137日であった．ERCP後膵炎に寄与する因子として膵癌か否か，主
膵管の閉塞の有無，ステント留置前のESTの有無，PSかMS，MSにおけるcoverかuncover，SEMSの径が8 mm 
か 10 mmの6因子にて多変量解析したところいずれも寄与しなかった．
【結論】悪性胆道狭窄に対する内視鏡的胆管ステント留置においてステントの種類や径，ステント留置前のEST
の有無はERCP後膵炎に寄与しない．
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